Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


4Q preview: Amgen, Biogen, BMS, Celgene, Novartis, Pfizer and Roche

This article was originally published in Scrip

Executive Summary

The full-year reporting season began on 21 January with Johnson & Johnson reporting a strong showing from pharma sales (helped from an expected short-lived boost from its hepatitis C newcomer Olysio (simeprevir). Its fourth-quarter figures already showed the effects of "currency headwinds" that are expected to impact many in its pharma peer set in 2015. It warned that foreign exchange shifts with the recent strong appreciation of the US dollar will weigh on its 2015 figures. Goldman Sachs analysts believe big US pharma companies will take a 4-6% hit from currency headwinds in 2015, with about 37-50% of the top line hit flowing to EPS.

You may also be interested in...

Snapshot: April Highlights

A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series. 

Transforming Patient Engagement At Novartis

Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action. 

In Vivo's 2022 Rising Leaders At A Glance

Top 30 Leaders: see the list of entrepreneurs and innovators highlighted in the third edition of In Vivo's Rising Leaders series. 


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts